AR054526A1 - Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1) - Google Patents

Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)

Info

Publication number
AR054526A1
AR054526A1 ARP060102795A ARP060102795A AR054526A1 AR 054526 A1 AR054526 A1 AR 054526A1 AR P060102795 A ARP060102795 A AR P060102795A AR P060102795 A ARP060102795 A AR P060102795A AR 054526 A1 AR054526 A1 AR 054526A1
Authority
AR
Argentina
Prior art keywords
muc
amino acid
acid sequence
glicoprotein
tarting
Prior art date
Application number
ARP060102795A
Other languages
English (en)
Spanish (es)
Inventor
Michael B Longenecker
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of AR054526A1 publication Critical patent/AR054526A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
ARP060102795A 2005-06-28 2006-06-28 Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1) AR054526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69423305P 2005-06-28 2005-06-28

Publications (1)

Publication Number Publication Date
AR054526A1 true AR054526A1 (es) 2007-06-27

Family

ID=37708986

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102795A AR054526A1 (es) 2005-06-28 2006-06-28 Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)

Country Status (16)

Country Link
US (3) US8871250B2 (enExample)
EP (2) EP2366400B1 (enExample)
JP (3) JP5364371B2 (enExample)
CN (2) CN105194650A (enExample)
AR (1) AR054526A1 (enExample)
AU (1) AU2006274651B2 (enExample)
BR (1) BRPI0613510A2 (enExample)
CA (1) CA2613327A1 (enExample)
DK (2) DK1896051T3 (enExample)
ES (2) ES2526344T3 (enExample)
HK (1) HK1219417A1 (enExample)
HU (1) HUE026490T2 (enExample)
PL (2) PL1896051T3 (enExample)
PT (2) PT2366400E (enExample)
TW (2) TWI511738B (enExample)
WO (1) WO2007015171A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
MX2011006562A (es) * 2008-12-17 2011-09-27 Oncothyreon Inc Metodo para elaborar liposomas pequeños.
BRPI1009892A2 (pt) * 2009-03-24 2016-03-15 Transgène S A método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
BRPI1010512A2 (pt) * 2009-04-17 2016-03-15 Transgène S A "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
GB0910751D0 (en) 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
EP2452194B1 (en) 2009-07-10 2015-11-11 Transgene SA Biomarker for selecting patients and related methods
US9346867B2 (en) 2010-04-19 2016-05-24 Sumitomo Bakelite Co., Ltd. Cancer-related glycopeptide epitopes, antibodies and methods of use
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
JP2016520073A (ja) * 2013-05-14 2016-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｍｕｃ−１リポペプチドによるワクチン免疫で肺癌を治療する方法
BR112016000889A2 (pt) * 2013-08-21 2017-12-12 Curevac Ag composição e vacina para tratamento de câncer de próstata
US9467478B1 (en) 2013-12-18 2016-10-11 vIPtela Inc. Overlay management protocol for secure routing based on an overlay network
WO2015099224A1 (ko) 2013-12-26 2015-07-02 주식회사 포스코 압연장치, 연주압연장치 및 방법
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CN112190688A (zh) * 2020-09-09 2021-01-08 广州医科大学附属第一医院（广州呼吸中心） 粘蛋白muc1在制备具有延缓肺衰老功效的药物中的应用
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
WO2026011417A1 (en) * 2024-07-12 2026-01-15 The Hong Kong University Of Science And Technology Compositions and methods involving artificial poly (a) sequences

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
ATE72123T1 (de) 1985-04-19 1992-02-15 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en) * 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1997034921A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
WO1997038010A2 (en) 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
DE69839443D1 (de) * 1997-05-08 2008-06-19 Biomira Inc Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
WO2001018035A2 (en) 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
US7491707B1 (en) 1999-11-15 2009-02-17 Biomira, Inc. Synthetic lipid-a-analogs and uses thereof
CA2404327A1 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
DE60134265D1 (de) * 2000-12-01 2008-07-10 Biomira Inc Herstellung grosser liposome durch infusion in peg
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
WO2003003985A2 (en) 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
EP1572918B1 (en) 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
JP5014573B2 (ja) 2002-05-09 2012-08-29 オンコサイレオン インコーポレーテッド 脂質ａおよび他の炭水化物リガンド類似体
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)

Also Published As

Publication number Publication date
PT2366400E (pt) 2016-02-02
PT1896051E (pt) 2015-01-13
TWI511738B (zh) 2015-12-11
HK1219417A1 (zh) 2017-04-07
TW201615208A (zh) 2016-05-01
PL1896051T3 (pl) 2015-04-30
JP5858894B2 (ja) 2016-02-10
EP1896051B1 (en) 2014-10-15
WO2007015171A2 (en) 2007-02-08
WO2007015171A3 (en) 2007-06-14
JP2016014046A (ja) 2016-01-28
US8871250B2 (en) 2014-10-28
DK1896051T3 (en) 2015-01-05
ES2558131T3 (es) 2016-02-02
US20150071990A1 (en) 2015-03-12
US20150359868A1 (en) 2015-12-17
EP1896051A4 (en) 2008-08-27
HUE026490T2 (en) 2016-06-28
EP2366400B1 (en) 2015-09-30
US9119784B2 (en) 2015-09-01
US20070014844A1 (en) 2007-01-18
ES2526344T3 (es) 2015-01-09
BRPI0613510A2 (pt) 2011-01-11
TW200738253A (en) 2007-10-16
JP2008546833A (ja) 2008-12-25
AU2006274651A1 (en) 2007-02-08
CA2613327A1 (en) 2007-02-08
AU2006274651B2 (en) 2012-09-27
DK2366400T3 (en) 2016-01-11
CN101309697A (zh) 2008-11-19
JP5364371B2 (ja) 2013-12-11
PL2366400T3 (pl) 2016-03-31
EP2366400A1 (en) 2011-09-21
CN105194650A (zh) 2015-12-30
EP1896051A2 (en) 2008-03-12
JP2013047234A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
AR051350A1 (es) Vacuna de glucoproteina mucinosa (muc-1)
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
BR0113006A (pt) Método para tratar doença de armazenamento de glicogênio tipo ii num indivìduo e seu uso
CY1115841T1 (el) Εμβολια πεπτιδιου παραγομενα απο epha4
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
EP2493507A4 (en) AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
RU2016113055A (ru) Композиция для лечения и профилактики доброкачественной гиперплазии простаты
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
TW200738253A (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
ATE514718T1 (de) Peptabody für krebsbehandlung
EP1401467A4 (en) ALPHA FETOPROTEIN PEPTIDES AND THEIR USE
SE0401631L (sv) Ny sammansättning
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells
AR073967A1 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen al mismo
WO2007120555A3 (en) Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism
MX2022003100A (es) Un inmunoterapeutico para el tratamiento del cancer de prostata.
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN

Legal Events

Date Code Title Description
FB Suspension of granting procedure